News | Radiology Business | December 18, 2019

Notification of company split related to diagnostic imaging-related business and transfer of shares of a new company, and recognition of extraordinary gain on an unconsolidated basis and other income on a consolidated basis for fiscal year ending March 31, 2021

Notification of company split related to diagnostic imaging-related business and transfer of shares of a new company, and recognition of extraordinary gain on an unconsolidated basis and other income on a consolidated basis for fiscal year ending March 31, 2021

December 18, 2019 —New details have just been released regarding Fujifilm’s purchase of Hitachi Medical Systems. According to a press statement issued by Hitachi, the company has decided to execute an absorption-type split (the “Company Split”) involving the diagnostic imaging-related business (the “Business”), currently undertaken by Hitachi and its consolidated subsidiaries and affiliate companies, through which the Business will be transferred to a newly established company serving as a successor company (the “New Company”), and transfer all shares in the New Company to FUJIFILM Corporation (TSE: 4901, “Fujifilm”) (such share transfer, the “Share Transfer”) after the Company Split.

Hitachi and Fujifilm agreed to the enterprise value of the Business as 179 billion yen. The final purchase price will be determined after customary adjustments for net working capital and net debt based on actual amounts at the closing date. The Company Split and the Share Transfer are subject to customary closing conditions and regulatory approvals. Disclosure regarding the Company Split in this announcement is simplified since the Company Split is an absorption-type split in which the Business is transferred from Hitachi to the New Company, a wholly-owned subsidiary of Hitachi.

Purpose of the Company Split and the Share Transfer

Hitachi operates diagnostic imaging-related businesses, such as diagnostic imaging equipment and electronic medical record businesses globally. Hitachi has made efforts in strengthening the Business and establishing an efficient management structure, including the reorganization of Hitachi Medical Corp. and Hitachi Aloka Medical, Ltd. in 2016.

The diagnostic imaging-related business is expected to see steady growth due to aging populations and increase in chronic diseases in developed markets, as well as demand for improved levels of healthcare alongside economic growth in emerging countries. At the same time, scale expansion is becoming increasingly critical for the Business in the face of advances in industrial consolidation and intensifying global competition. With this in mind, Hitachi decided on the Share Transfer to Fujifilm on concluding that the Share Transfer is optimal in strengthening competitiveness of and achieving further growth in the Business given Fujifilm’s highly complementary sales channels and outstanding technological capabilities in fields such as image processing.

Hitachi, in its healthcare business, will accelerate global rollout of its particle therapy treatment systems, a highly reliable system with outstanding track record of treating over 60,000 patients, strengthen its in-vitro diagnostic systems business that enables early detection of diseases, and for the future, Hitachi will expand its cell manufacturing solutions deploying its expertise in regenerative medicine. Hitachi will also continue to offer high value-added services in the IT field, such as medical and nursing data linkage platform and new services utilizing AI and analytics. Furthermore, Hitachi will broaden its healthcare business into group-wide efforts by leveraging its strengths in digital technologies to create social, environmental, and economic values and contribute to the realization of a sustainable society.

Outline of the Company Split and the Share Transfer

Schedule of the Company Split and the Share Transfer

  • Signing of the share purchase agreement: December 18, 2019
  • Signing of the company split agreement: To be determined
  • Effective date for Company Split and close date of Share Transfer: July 1, 2020 (tentative)

(*) The transaction is subject to customary closing conditions and regulatory approvals. Hitachi will perform the Company Split without holding general meetings or shareholder to obtain approval for the absorption-type split agreement since the Company Split falls under an “abbreviated split” as set forth in Paragraph 2, Article 784 of the Company Act with respect to Hitachi.

 

Company split method: The split is an absorption-type split under which Hitachi will be the splitting company and the New Company will be the succeeding company.

Handling of stock acquisition rights and bonds with stock acquisition rights accompanying Company Split: There will be no changes in the handling of stock acquisition rights issued by Hitachi due to the Company Split. Hitachi has no bonds with stock acquisition rights.

Capitalization changes accompanying Company Split: There will be no changes in Hitachi’s capitalization as a result of the Company Split.

Other: Other details related to the Company Split will be disclosed once determined.

 

Related content:

Fujifilm Contemplating Purchase of Hitachi Medical Systems

 

Related Content

News | Magnetic Resonance Imaging (MRI)

December 1, 2021 — In the first MRI-based study to investigate prenatal alcohol exposure, researchers found significant ...

Time December 01, 2021
arrow
News | Computed Tomography (CT)

December 1, 2021 — Researchers in Germany identified bone disease in the fossilized jaw of a Tyrannosaurus rex using a ...

Time December 01, 2021
arrow
News | Coronavirus (COVID-19)

November 30, 2021 — COVID-19 of mild to moderate severity in pregnant women appears to have no effect on the brain of ...

Time November 30, 2021
arrow
News | Computed Tomography (CT)

November 30, 2021 — A three-year study of more than 1,000 patients found that the risk of delayed intracranial ...

Time November 30, 2021
arrow
News | Coronavirus (COVID-19)

November 29, 2021 — The largest multi-institutional international study to date on brain complications of COVID-19 has ...

Time November 29, 2021
arrow
News | Coronavirus (COVID-19)

November 29, 2021 — A small but significant percentage of college athletes with COVID-19 develop myocarditis, a ...

Time November 29, 2021
arrow
News | Artificial Intelligence

November 28, 2021 — Lunit, a medical AI provider, is returning to the 107th Radiological Society of North America (RSNA) ...

Time November 28, 2021
arrow
News | Computed Tomography (CT)

November 28, 2021 — Detection Technology, a leader in X-ray detector solutions, unveiled the industry’s first off-the ...

Time November 28, 2021
arrow
News | Artificial Intelligence

November 28, 2021 — Rhino Health announced a pilot project with the pancreatic cancer working group of the Early ...

Time November 28, 2021
arrow
News | Enterprise Imaging

November 28, 2021 — Aidoc, a provider of artificial intelligence (AI) solutions for medical imaging, announced the ...

Time November 28, 2021
arrow
Subscribe Now